Developer docs
API playgroundTry for free, no card

Search company profiles

Scendea

Full company profile

uuid000c4l3

Namestring
Scendea
Legal namestring
Scendea Ltd
Websiteurl
scendea.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Scendea is an international product development, regulatory, and compliance consulting group headquartered in Bishop's Stortford, United Kingdom, with operational offices in Washington DC, San Diego, Amsterdam, and Brisbane. Founded in 2004 as a management buyout of the product development and regulatory consulting function of a clinical research organisation, the firm serves pharmaceutical and biotechnology companies ranging from academic spin-outs to large pharma, alongside investors in life sciences. Across more than 20 years of operation, Scendea reports involvement in over 1,000 development programmes covering more than 100 indications and 25 therapeutic areas, with particular depth in oncology, infectious disease, respiratory, and rare/orphan indications. The firm holds B Corp certification and received the King's Award for Enterprise for International Trade in 2024.

The company's offering is organised into four core service pillars — Non-Clinical (toxicology and safety pharmacology consulting), CMC (chemistry, manufacturing, and controls), Clinical (clinical development plans, regulatory submissions including IND, CTA, NDA, BLA, MAA, and programme management), and Regulatory (global strategy for US, EU, and UK) — supported by a dedicated Compliance division delivering GxP Audits, CRO/CDMO Oversight, Quality Management System support, and GxP Training. There is no proprietary software platform, algorithms, or hardware product; the underlying "technology" is the institutional expertise of a bench of senior consultants that includes a former FDA Chief Pediatrician, ex-FDA pharmaceutical chemists and investigative analysts, former MHRA Senior Medical and Non-Clinical Assessors, a former UK GCP Inspector, and ex-executives from PPD, GSK, AstraZeneca, Johnson & Johnson, Amgen, Lonza, and Daiichi Sankyo. The firm's CMO, Dr Maria Beatrice Panico, received the 2023 TOPRA Award for Regulatory Excellence (Lifetime Achievement).

Scendea monetises through three engagement models — Ad Hoc (pay-as-you-go), Project Based (fixed scope, defined budget), and Partial FTE (dedicated expert allocation over a flexible period) — with all pricing quote-based and not publicly disclosed. The go-to-market motion is enterprise field sales led by senior consultants, complemented by thought-leadership content (regulatory intelligence blog, whitepapers), conference attendance (BIO International, DIA, LSX Congress, Bio Connections Australia, Cell & Gene Meeting on the Mesa), LinkedIn engagement, and partner referrals. Strategic alliances with Japan's CUES Consulting (announced August 2024), pharmacovigilance provider Signal, and joint thought-leadership with ERBC and FGK extend geographic reach into Japan and broaden the integrated service offering.

Short descriptiontext

Scendea is a UK-headquartered product development, regulatory, and compliance consulting group serving pharmaceutical, biotech, academic spin-out, and investor clients globally, with offices in the US, Netherlands, and Australia and expertise across 25 therapeutic areas.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWashington, United States
HQ citystring
Washington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regulatory affairs consulting, pharmaceutical product development, biotech regulatory strategy, GxP compliance auditing, clinical development consulting
Industry4 codes
PRIMARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
NAICS code3 codes
  • Other Scientific and Technical Consulting Services54169
  • Other Management Consulting Services541618
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Management Consulting Services8742
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Regulatory & Product Development Consulting
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Regulatory & Product Development Consulting Services
TypeProfessional Services
Description

Scendea generates revenue by providing consulting services across Non-Clinical, CMC, Clinical, Regulatory, and Compliance. Engagement models include Ad Hoc (pay-as-you-go), Project Based (fixed-scope), and Partial FTE (dedicated expert allocation). Services are delivered by a global team of experienced consultants to pharmaceutical and biotech clients worldwide.

scendea.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details3 tiers
1Ad Hoc Consulting
ModelOtherBilling cadencePay-as-you-go
Notes

Pay-as-you-go solution ideal for smaller activities required on a rapid timescale. Quote-based / not publicly disclosed.

scendea.com
2Project Based
ModelOtherBilling cadenceMulti-year contract
Notes

Ideal for larger activities with a clear scope. Scendea works closely with clients to build a bespoke solution and define a budget accordingly. Quote-based / not publicly disclosed.

scendea.com
3Partial FTE
ModelOtherBilling cadencePay-as-you-go
Notes

Allocation of a dedicated expert for a flexible period, offering higher degree of integration with client's activities. Considerably more cost effective than full-time hire; allows adjustment of utilisation at any given time without penalty. Quote-based / not publicly disclosed.

scendea.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Scendea is an international product development, regulatory, and compliance consulting firm that delivers scientific, regulatory, and quality consulting services to pharmaceutical and biotechnology companies. Its core offering spans Non-Clinical (toxicology/safety), CMC (chemistry, manufacturing and controls), Clinical (development, submissions, programme management), Regulatory (global strategy for US/EU/UK), and Compliance (GxP audits, CRO/CDMO oversight, QMS support, GxP training) services, delivered via Ad Hoc, Project-Based, and Partial FTE engagement models by former regulatory agency assessors and pharma executives.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Over 1,000 development programmes supported
+4 more records
Product overview1 text field

Scendea is a consulting group offering a portfolio of specialised services rather than a unified software product. The core service suite spans four interconnected areas: Non-Clinical Services (toxicology and safety assessment consulting), CMC Services (chemistry, manufacturing and controls), Clinical Services (clinical development, regulatory submissions and programme management), and Regulatory Services (global regulatory strategy for US, EU and UK markets). These are supported by a dedicated Compliance division delivering four service modules: GxP Audits (GLP, GCP, GMP, GVP audit programmes), CRO & CDMO Oversight (contract research and manufacturing organisation governance), Quality Management System (QMS) Support (gap analysis, QMS development, investigations), and GxP Training (tailored compliance training). Clients can engage via Ad Hoc consulting, Project-Based engagements with defined scope and budget, or the Partial FTE model for dedicated expert allocation over a flexible period.

Product and service9 records
1Non-Clinical Services
CategoryCore consulting service
Description

Non-clinical scientific and regulatory consulting covering toxicology, safety pharmacology, and regulatory affairs to support pre-clinical development programmes for pharmaceutical and biotechnology clients.

2CMC Services
CategoryCore consulting service
Description

Chemistry, Manufacturing and Controls consulting providing global CMC technical and regulatory advice from early-stage development through to marketing authorisation and post-marketing phases for pharmaceutical and biotechnology clients.

3Clinical Services
CategoryCore consulting service
Description

Clinical development and operational support including Clinical Development Plan creation, gap analysis, clinical study reports, protocol development, regulatory submissions (IND, CTA, NDA, BLA, MAA), agency interactions, and programme/project management.

4Regulatory Services
CategoryCore consulting service
Description

Global regulatory strategy consulting for US, EU and UK markets covering designations, Target Product Profile development, pre-submission interactions, and procedural management for marketing authorisation.

5GxP Audits
CategoryCompliance consulting service
Description

Comprehensive GxP audit services covering GLP, GCP, GMP and GVP across systems, studies and vendors, including inspection readiness support and issue resolution for pharmaceutical and biotech clients.

6CRO & CDMO Oversight
CategoryCompliance consulting service
Description

Expert oversight services for non-clinical and clinical Contract Research Organisations and Contract Development and Manufacturing Organisations to maintain quality, safety and compliance throughout product development.

7Quality Management System (QMS) Support
CategoryCompliance consulting service
Description

Practical and scalable support to develop, assess and maintain compliant and effective Quality Management Systems, covering gap analysis, QMS development, and investigations and root cause analysis.

8GxP Training
CategoryCompliance consulting service
Description

Tailored GxP training across GCP, GLP, GMP and GVP frameworks, delivered onsite or remotely to support compliance, internal capability development and inspection readiness for pharmaceutical and biotech clients.

9Partial FTE Solution
CategoryEngagement model
Description

Flexible engagement model providing access to Scendea's expert consultants for a dedicated period, allowing clients to integrate specialist regulatory and product development expertise without long-term commitments; more cost-effective than full-time hires.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-27
Description

Scendea announced a strategic partnership with CUES Consulting in August 2024. CUES Consulting specialises in Japanese regulatory affairs, safety management, and post-marketing surveillance. Together, the two firms assist clients seeking Japanese regulatory approval for their medicinal products, providing comprehensive support from product development through to market introduction in Japan. The partnership extends Scendea's geographic reach and regulatory expertise into the Japanese market.

2Signal (Pharmacovigilance Partner)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Scendea's GVP (Good Pharmacovigilance Practice) services are delivered by its pharmacovigilance partner, Signal. This partnership enables Scendea to provide clients with reliable, expert pharmacovigilance support in line with global regulatory requirements, complementing Scendea's core regulatory and compliance consulting services.

scendea.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Scendea collaborated with ERBC on a joint whitepaper titled 'Lead Optimisation & Drug-Induced Cardiotoxicity'. Scendea authors Dr Erik Doevendans and Ellen Wilkinson worked alongside ERBC authors Pascal Champeroux and Raafat Fares. This collaboration produces thought leadership content combining Scendea's regulatory expertise with ERBC's non-clinical/cardiotoxicology specialisation.

4FGK (Represented in EU CTR Whitepaper)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Scendea collaborated with FGK (a German regulatory consultancy) on a whitepaper titled 'Clinical Trial Regulation: A New Chapter for EU Clinical Trials'. Authored by Scendea Senior Consultant Amy Cooke, Principal Consultant Dr Maria Beatrice Panico, and FGK's Director of Regulatory Affairs Dr Uwe Kramer. This joint publication positions both firms as thought leaders in EU Clinical Trials Regulation.

scendea.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1CUES Consulting
TypeDirect peer
Description

Tokyo-based regulatory affairs and pharmacovigilance consultancy. Now a Scendea strategic partner, but historically a peer in the Japanese regulatory services market for Western biotechs — direct overlap on PMDA-side regulatory work.

TypeBroad incumbent
Description

Top-5 global CRO offering comprehensive regulatory, clinical, CMC, and post-marketing services to large pharma and biotech. Overlaps with Scendea on regulatory strategy, but operates at vastly greater scale and as part of a full-service delivery platform.

TypeDirect peer
Description

Paris- and US-headquartered boutique regulatory and product development consultancy serving pharma and biotech with regulatory strategy, CMC, and clinical development services. Closely comparable to Scendea in service mix, boutique scale, and global delivery model.

4FGK Representative Service
TypeDirect peer
Description

Munich-based regulatory consultancy and EU/UK/EEA MAH representative. Aligned with Scendea's European regulatory offering; the two firms have co-authored EU CTR thought leadership, confirming direct competitive and peer overlap.

TypeDirect peer
Description

Sweden-based regulatory and product development consultancy with strong CMC, clinical, and regulatory affairs offerings to pharma and biotech. Comparable mid-size boutique competitor with similar global footprint and ex-regulator talent base.

TypeDirect peer
Description

Global regulatory, compliance, and pharmacovigilance consultancy (recently acquired by AmerisourceBergen). Highly comparable in mid-large regulatory consulting scale with strong GxP audit and quality services portfolio.

TypeBroad incumbent
Description

Global CRO with substantial regulatory and product development consulting practices (post-PRA Health Sciences). Competes with Scendea for biotech regulatory work but offers a far broader clinical and lab services portfolio.

TypeDirect peer
Description

European non-clinical and regulatory consulting group with deep toxicology, safety pharmacology, and CMC capabilities. Comparable in non-clinical services portfolio and regulatory navigation offerings.

9Diamond Pharma Services
TypeDirect peer
Description

UK-based regulatory affairs and pharmacovigilance consultancy supporting pharma and biotech. Overlapping services (regulatory strategy, GxP compliance, PV) and similar boutique positioning; Paul Cronin previously held senior roles here.

10ERA Consulting (now Pharmalex)
TypeDirect peer
Description

Regulatory and product development consultancy specializing in biologics, biosimilars, ATMPs, and CMC — comparable in scope and therapeutic-area depth to Scendea. Paul Cronin (Scendea Director) previously held senior roles at ERA, illustrating direct talent overlap.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Scendea

Pharmaceutical Regulatory & Product Development Consultingscendea.com

Scendea is a UK-headquartered product development, regulatory, and compliance consulting group serving pharmaceutical, biotech, academic spin-out, and investor clients globally, with offices in the US, Netherlands, and Australia and expertise across 25 therapeutic areas.

What Scendea does

Scendea is an international product development, regulatory, and compliance consulting group headquartered in Bishop's Stortford, United Kingdom, with operational offices in Washington DC, San Diego, Amsterdam, and Brisbane. Founded in 2004 as a management buyout of the product development and regulatory consulting function of a clinical research organisation, the firm serves pharmaceutical and biotechnology companies ranging from academic spin-outs to large pharma, alongside investors in life sciences. Across more than 20 years of operation, Scendea reports involvement in over 1,000 development programmes covering more than 100 indications and 25 therapeutic areas, with particular depth in oncology, infectious disease, respiratory, and rare/orphan indications. The firm holds B Corp certification and received the King's Award for Enterprise for International Trade in 2024.

The company's offering is organised into four core service pillars — Non-Clinical (toxicology and safety pharmacology consulting), CMC (chemistry, manufacturing, and controls), Clinical (clinical development plans, regulatory submissions including IND, CTA, NDA, BLA, MAA, and programme management), and Regulatory (global strategy for US, EU, and UK) — supported by a dedicated Compliance division delivering GxP Audits, CRO/CDMO Oversight, Quality Management System support, and GxP Training. There is no proprietary software platform, algorithms, or hardware product; the underlying "technology" is the institutional expertise of a bench of senior consultants that includes a former FDA Chief Pediatrician, ex-FDA pharmaceutical chemists and investigative analysts, former MHRA Senior Medical and Non-Clinical Assessors, a former UK GCP Inspector, and ex-executives from PPD, GSK, AstraZeneca, Johnson & Johnson, Amgen, Lonza, and Daiichi Sankyo. The firm's CMO, Dr Maria Beatrice Panico, received the 2023 TOPRA Award for Regulatory Excellence (Lifetime Achievement).

Scendea monetises through three engagement models — Ad Hoc (pay-as-you-go), Project Based (fixed scope, defined budget), and Partial FTE (dedicated expert allocation over a flexible period) — with all pricing quote-based and not publicly disclosed. The go-to-market motion is enterprise field sales led by senior consultants, complemented by thought-leadership content (regulatory intelligence blog, whitepapers), conference attendance (BIO International, DIA, LSX Congress, Bio Connections Australia, Cell & Gene Meeting on the Mesa), LinkedIn engagement, and partner referrals. Strategic alliances with Japan's CUES Consulting (announced August 2024), pharmacovigilance provider Signal, and joint thought-leadership with ERBC and FGK extend geographic reach into Japan and broaden the integrated service offering.

Scendea firmographics

Firmographics
Name
Scendea
Legal name
Scendea Ltd
Website
https://scendea.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
51–100 employees
Short description
Scendea is a UK-headquartered product development, regulatory, and compliance consulting group serving pharmaceutical, biotech, academic spin-out, and investor clients globally, with offices in the US, Netherlands, and Australia and expertise across 25 therapeutic areas.
Ownership category
akta.pro rank

Scendea industry classification

Industry
Product category
Pharmaceutical Regulatory & Product Development Consulting
NAICS
Other Scientific and Technical Consulting Services (54169), Other Management Consulting Services (541618), Scientific Research and Development Services (5417)
SIC
Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs

Keywords

  • Regulatory affairs consulting
  • Pharmaceutical product development
  • Biotech regulatory strategy
  • GxP compliance auditing
  • Clinical development consulting

Where Scendea is headquartered

Location

Headquarters

HQ city
Washington
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Scendea business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Regulatory & Product Development Consulting Services: Scendea generates revenue by providing consulting services across Non-Clinical, CMC, Clinical, Regulatory, and Compliance. Engagement models include Ad Hoc (pay-as-you-go), Project Based (fixed-scope), and Partial FTE (dedicated expert allocation). Services are delivered by a global team of experienced consultants to pharmaceutical and biotech clients worldwide.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goAd Hoc Consulting
OtherMulti-year contractProject Based
OtherPay-as-you-goPartial FTE

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Scendea product offering

Product offering

Core offering

Scendea is an international product development, regulatory, and compliance consulting firm that delivers scientific, regulatory, and quality consulting services to pharmaceutical and biotechnology companies. Its core offering spans Non-Clinical (toxicology/safety), CMC (chemistry, manufacturing and controls), Clinical (development, submissions, programme management), Regulatory (global strategy for US/EU/UK), and Compliance (GxP audits, CRO/CDMO oversight, QMS support, GxP training) services, delivered via Ad Hoc, Project-Based, and Partial FTE engagement models by former regulatory agency assessors and pharma executives.

Product overview

Scendea is a consulting group offering a portfolio of specialised services rather than a unified software product. The core service suite spans four interconnected areas: Non-Clinical Services (toxicology and safety assessment consulting), CMC Services (chemistry, manufacturing and controls), Clinical Services (clinical development, regulatory submissions and programme management), and Regulatory Services (global regulatory strategy for US, EU and UK markets). These are supported by a dedicated Compliance division delivering four service modules: GxP Audits (GLP, GCP, GMP, GVP audit programmes), CRO & CDMO Oversight (contract research and manufacturing organisation governance), Quality Management System (QMS) Support (gap analysis, QMS development, investigations), and GxP Training (tailored compliance training). Clients can engage via Ad Hoc consulting, Project-Based engagements with defined scope and budget, or the Partial FTE model for dedicated expert allocation over a flexible period.

Differentiator

Problem solved

Functional benefit

Products and services

  • Non-Clinical Services Non-clinical scientific and regulatory consulting covering toxicology, safety pharmacology, and regulatory affairs to support pre-clinical development programmes for pharmaceutical and biotechnology clients.
  • CMC Services Chemistry, Manufacturing and Controls consulting providing global CMC technical and regulatory advice from early-stage development through to marketing authorisation and post-marketing phases for pharmaceutical and biotechnology clients.
  • Clinical Services Clinical development and operational support including Clinical Development Plan creation, gap analysis, clinical study reports, protocol development, regulatory submissions (IND, CTA, NDA, BLA, MAA), agency interactions, and programme/project management.
  • Regulatory Services Global regulatory strategy consulting for US, EU and UK markets covering designations, Target Product Profile development, pre-submission interactions, and procedural management for marketing authorisation.
  • GxP Audits Comprehensive GxP audit services covering GLP, GCP, GMP and GVP across systems, studies and vendors, including inspection readiness support and issue resolution for pharmaceutical and biotech clients.
  • CRO & CDMO Oversight Expert oversight services for non-clinical and clinical Contract Research Organisations and Contract Development and Manufacturing Organisations to maintain quality, safety and compliance throughout product development.
  • Quality Management System (QMS) Support Practical and scalable support to develop, assess and maintain compliant and effective Quality Management Systems, covering gap analysis, QMS development, and investigations and root cause analysis.
  • GxP Training Tailored GxP training across GCP, GLP, GMP and GVP frameworks, delivered onsite or remotely to support compliance, internal capability development and inspection readiness for pharmaceutical and biotech clients.
  • Partial FTE Solution Flexible engagement model providing access to Scendea's expert consultants for a dedicated period, allowing clients to integrate specialist regulatory and product development expertise without long-term commitments; more cost-effective than full-time hires.

Quantifiable outcome

  • Over 1,000 development programmes supported
  • +4 more outcomes

Companies that use Scendea

Customer profile

Segments3 records

Ideal customer profiles3 records

Scendea technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Scendea partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • CUES ConsultingcoreStrategic or Co-development Partner · 27 August 2024Scendea announced a strategic partnership with CUES Consulting in August 2024. CUES Consulting specialises in Japanese regulatory affairs, safety management, and post-marketing surveillance. Together, the two firms assist clients seeking Japanese regulatory approval for their medicinal products, providing comprehensive support from product development through to market introduction in Japan. The partnership extends Scendea's geographic reach and regulatory expertise into the Japanese market.
  • Signal (Pharmacovigilance Partner)coreStrategic or Co-development PartnerScendea's GVP (Good Pharmacovigilance Practice) services are delivered by its pharmacovigilance partner, Signal. This partnership enables Scendea to provide clients with reliable, expert pharmacovigilance support in line with global regulatory requirements, complementing Scendea's core regulatory and compliance consulting services.
  • ERBC (European Regulatory & Biology Consulting)minorStrategic or Co-development PartnerScendea collaborated with ERBC on a joint whitepaper titled 'Lead Optimisation & Drug-Induced Cardiotoxicity'. Scendea authors Dr Erik Doevendans and Ellen Wilkinson worked alongside ERBC authors Pascal Champeroux and Raafat Fares. This collaboration produces thought leadership content combining Scendea's regulatory expertise with ERBC's non-clinical/cardiotoxicology specialisation.
  • FGK (Represented in EU CTR Whitepaper)minorStrategic or Co-development PartnerScendea collaborated with FGK (a German regulatory consultancy) on a whitepaper titled 'Clinical Trial Regulation: A New Chapter for EU Clinical Trials'. Authored by Scendea Senior Consultant Amy Cooke, Principal Consultant Dr Maria Beatrice Panico, and FGK's Director of Regulatory Affairs Dr Uwe Kramer. This joint publication positions both firms as thought leaders in EU Clinical Trials Regulation.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Scendea competitors and assessment

Company assessment

Direct peers

  • CUES Consulting: Tokyo-based regulatory affairs and pharmacovigilance consultancy. Now a Scendea strategic partner, but historically a peer in the Japanese regulatory services market for Western biotechs — direct overlap on PMDA-side regulatory work.
  • Voisin Consulting Life Sciences: Paris- and US-headquartered boutique regulatory and product development consultancy serving pharma and biotech with regulatory strategy, CMC, and clinical development services. Closely comparable to Scendea in service mix, boutique scale, and global delivery model.
  • FGK Representative Service: Munich-based regulatory consultancy and EU/UK/EEA MAH representative. Aligned with Scendea's European regulatory offering; the two firms have co-authored EU CTR thought leadership, confirming direct competitive and peer overlap.
  • NDA Group: Sweden-based regulatory and product development consultancy with strong CMC, clinical, and regulatory affairs offerings to pharma and biotech. Comparable mid-size boutique competitor with similar global footprint and ex-regulator talent base.
  • ProPharma Group: Global regulatory, compliance, and pharmacovigilance consultancy (recently acquired by AmerisourceBergen). Highly comparable in mid-large regulatory consulting scale with strong GxP audit and quality services portfolio.
  • ERBC (European Regulatory & Biology Consulting): European non-clinical and regulatory consulting group with deep toxicology, safety pharmacology, and CMC capabilities. Comparable in non-clinical services portfolio and regulatory navigation offerings.
  • Diamond Pharma Services: UK-based regulatory affairs and pharmacovigilance consultancy supporting pharma and biotech. Overlapping services (regulatory strategy, GxP compliance, PV) and similar boutique positioning; Paul Cronin previously held senior roles here.
  • ERA Consulting (now Pharmalex): Regulatory and product development consultancy specializing in biologics, biosimilars, ATMPs, and CMC — comparable in scope and therapeutic-area depth to Scendea. Paul Cronin (Scendea Director) previously held senior roles at ERA, illustrating direct talent overlap.

Broad incumbents

  • Parexel International: Top-5 global CRO offering comprehensive regulatory, clinical, CMC, and post-marketing services to large pharma and biotech. Overlaps with Scendea on regulatory strategy, but operates at vastly greater scale and as part of a full-service delivery platform.
  • ICON plc: Global CRO with substantial regulatory and product development consulting practices (post-PRA Health Sciences). Competes with Scendea for biotech regulatory work but offers a far broader clinical and lab services portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Scendea social profiles

Digital presence

Scendea compliance and trust

Trust signal

Compliance2 records

Scendea financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Scendea leadership team

Management profile

Number of profiles

Profiles13 records

Scendea subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Scendea funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Scendea M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scendea

What does Scendea do?

Scendea is an international product development, regulatory, and compliance consulting firm that delivers scientific, regulatory, and quality consulting services to pharmaceutical and biotechnology companies. Its core offering spans Non-Clinical (toxicology/safety), CMC (chemistry, manufacturing and controls), Clinical (development, submissions, programme management), Regulatory (global strategy for US/EU/UK), and Compliance (GxP audits, CRO/CDMO oversight, QMS support, GxP training) services, delivered via Ad Hoc, Project-Based, and Partial FTE engagement models by former regulatory agency assessors and pharma executives.

Is Scendea a public or private company?

Scendea is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Scendea founded?

Scendea was founded in 2004. It employs 51 to 100 people.

Where is Scendea based?

Scendea is headquartered in Washington, United States, in the North America region.

How does Scendea make money?

One revenue line is on record: regulatory & Product Development Consulting Services.

Who are Scendea's main competitors?

Direct peers on record are CUES Consulting, Voisin Consulting Life Sciences, FGK Representative Service, NDA Group, ProPharma Group, ERBC (European Regulatory & Biology Consulting), Diamond Pharma Services and ERA Consulting (now Pharmalex). Broad incumbents are Parexel International and ICON plc.

Does Scendea have an API?

No public API is recorded for Scendea.

What industry is Scendea in?

Scendea's product category is Pharmaceutical Regulatory & Product Development Consulting. Its primary akta.pro industry code is HLAGAKAA, Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA), with a secondary code of HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight). Its NAICS code is 54169 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScendeaPost-Brexit Transition Period Changes. UK’s New Regulatory Landscape. — ScendeaA Scendea article outlines UK regulatory changes taking effect from 1 January 2021 as the MHRA becomes the independent medicines and devices regulator, covering clinical trials, orphan designation, licensing, pharmacovigilance and centrally authorised products. Key requirements include UK legal representatives, QP certification verification of investigational medicinal products, GB marketing authorisations for converted EU products, and a 12-month exemption for UK-based pharmacovigilance contacts.ScendeaFast Track Designation and Breakthrough Therapy Designation — ScendeaScendea, a regulatory consulting firm, published an educational article explaining the FDA's Fast Track and Breakthrough Therapy designation programs, which are designed to expedite the development and review of drugs for serious conditions. The article details the qualifying criteria, procedural requirements, and strategic timing recommendations for both programs, noting that Breakthrough Therapy designation requires preliminary clinical evidence of substantial improvement over available therapies while Fast Track designation can be requested with nonclinical data demonstrating potential to address unmet medical need. The firm recommends sponsors submit Fast Track requests as early as robust preclinical data is available and Breakthrough Therapy requests once clinical data is ready, ideally no later than the End of Phase 2 meeting, to maximize the benefits of FDA engagement throughout drug development.